Acute acrylamide exposure in male rodents results in reduced reproductive performance and dominant lethality. However, the reproductive effects of low-dose chronic exposure, which better reflects the nature of human exposure, remain far less certain. Human dietary consumption of acrylamide has been estimated at an average of 1-4 lg/kg bodyweight/day. In order to simulate this exposure, male mice were provided with acrylamide (1 lg/ ml) via their drinking water continuously for 6 mo, which was equivalent to a human dose of 10.5 lg/kg bodyweight/day. This exposure regime increased DNA damage in the spermatozoa without affecting a concomitant reduction in overall fertility. The offspring of acrylamide-treated mice did not have an increased incidence of skin papilloma formation following the two-stage tumor-induction protocol. However, the male offspring of acrylamide-treated fathers had significantly increased levels of DNA damage in their spermatozoa, despite having had no direct toxicant exposure. It was also found that the acrylamide-treated mice and, most crucially, their progeny had increased levels of CYP2E1 protein in their spermatocytes. This is significant because CYP2E1 is the sole enzyme responsible for conversion of acrylamide to its harmful metabolite glycidamide. This altered expression may be due to epigenetic alterations. Additionally, the F0 and F1 mice had increased oxidative adducts in the DNA of their germ cells, which was hypothesized to arise as a byproduct of increased CYP2E1 levels. Therefore, chronic paternal acrylamide exposure in mice has consequences for their offspring and raises concerns for the effects of acrylamide exposure in the human population and the accumulated effects with multiple generations of exposure.
INTRODUCTION
The contribution of male factors to infertility in humans is commonly overlooked, despite the convincing evidence for declining semen quality in many countries [1, 2] . While several studies have sought to assess the effects of maternal exposure to toxicants on the health of the offspring, such approaches are not suitable for toxicants such as acrylamide that elicit reproductive toxicity via male exposure [3, 4] . We are interested in the role of the genetic material contributed to fertilization by the spermatozoon, particularly as paternal exposure to toxins has long been known to be able to elevate the risk of cancer in the offspring [5] . We hypothesize that chronic exposure to the toxicant acrylamide also compromises the genetic and epigenetic material carried by the spermatozoa with negative implications for the health of offspring.
Studies of male mice have demonstrated that exposure to acute high doses of acrylamide leads to reduced fertility and reproductive toxicity (reviewed in Katen and Roman [6] ). Indeed, a single dose of 125 mg/kg bodyweight (bw) or 25 mg/ kg bw/day for 5 days leads to dominant lethal mutations following mating with unexposed females [7] [8] [9] [10] . Acute doses in male mice also have the potential to alter gene expression in resultant 1-, 2-, 4-, and 8-cell stage embryos, which has been proposed to have consequences for the future health of these offspring [11] . Similarly, subchronic acrylamide exposure at 4.2 mg /kg bw/day for 10 wk in male Long-Evans rats causes reduced copulatory and mounting activity, a reduction in fertility, and decreased sperm number and pup weights [3] . Hence, there are pronounced effects on fertility, and consequences to offspring, associated with both acute and subchronic paternal acrylamide exposure. Nevertheless, the fact that the doses used in these studies far exceed those of relevance to the general human population makes it difficult to draw definitive conclusions regarding risk.
It is widely established that acrylamide is formed during the cooking of carbohydrate-rich foods at temperatures exceeding 1208C [12] . This reaction occurs in foods such as breads, potato chips, cereals, and biscuits when a reducing sugar such as glucose reacts with an amino acid such as asparagine. Hence, humans are exposed to this toxicant in a chronic manner at an estimated average dose of 1-4 lg/kg bw/day [13] . This can be increased with other sources of acrylamide exposure, including cigarette smoking, and residual amounts of acrylamide in polyacrylamide, which is used in the paper, textiles, and cosmetics industries, as well as in the treatment of drinking water in some countries [14, 15] . These levels of human consumption are likely too low to cause reproductive toxicity based on the no-observed-adverse-effect level (NOAEL) determined in rats, which are 2 and 5 mg/kg bw/ day for premature embryonic death and reduced fertility, respectively [16] . However, there is mounting concern that chronic acrylamide exposure may have cumulative effects, particularly in view of the detrimental impacts observed in mice that had been subjected to a chronic treatment regime by Nixon et al. [17] . Indeed, the neurotoxic effects of acrylamide are cumulative. Chronic exposure (60 days to 2 yr) at doses of 1-20 mg/kg bw/day result in comparable neurotoxicity to acute doses (30-40 mg/kg bw/day) for shorter durations (10-30 days) [18] . Nevertheless, there is presently a lack of empirical evidence for the consequences of chronic exposure on the fertility of male mice and/or the health of their offspring.
The conversion of acrylamide to the more toxic metabolite glycidamide is essential for the reproductive toxicity observed in mice and has been found to occur solely via the detoxification enzyme CYP2E1 in both mice [10, 19, 20] and humans [21] . Glycidamide is highly reactive and readily capable of forming strong covalent adducts with DNA. CYP2E1-null mice consistently fail to produce any glycidamide upon exposure to acrylamide [19] , and accordingly, the dominant lethality seen in their wild-type counterparts is abrogated in the CYP2E1-null mice [10] . Work in our own laboratory has demonstrated that CYP2E1 is expressed in spermatocytes and that these cells are capable of metabolizing acrylamide to glycidamide in vitro [22] . Consistent with this conversion representing a first line of defense against acrylamide exposure, our work has also revealed that acrylamide elicits a rapid increase in Cyp2e1 mRNA transcript levels in these germ cells.
The aim of this study was to establish whether chronic paternal acrylamide exposure had a measurable impact on the integrity of the paternal genome within the germline carried on to future generations. Thus, we administered acrylamide via the drinking water to male mice at a dose of 1 lg/ml, which resulted in a dose of 0.13 mg/kg bw/day for 6 mo. When using the dose-translation method recommended by the Food and Drug Administration for conversion of NOAEL values determined in mice studies to the human equivalent dose (HED), we calculated the HED of acrylamide to be 10.5 lg/kg bw/day [23] , which is highly relevant to current human consumption estimates [13] . We then mated these males with unexposed females and assessed the susceptibility of the progeny to skin cancer induction using the standard tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) and tumor initiator 7,12-dimethylbenz [a] anthracene (DMBA)-FIG. 1. The male and female offspring of male mice exposed to chronic acrylamide treatments grow normally. A) The bodyweight of all F1 mice were recorded on a weekly basis from weaning throughout the two-stage tumor-induction protocol. No differences were seen between either male or female mice whose fathers were exposed to acrylamide or control. B) Testes of male F1 mice were weighed at completion of the study, and the testis to bodyweight ratios showed no difference between mice whose fathers were exposed to acrylamide compared to those exposed to control.
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induction protocol [24, 25] as well as assessing the DNA damage within the germ cells and spermatozoa of the F0 and F1 male mice. In order to relate perturbation of any of these parameters with acrylamide metabolism, we also sought to assess the expression levels of CYP2E1.
MATERIALS AND METHODS

Chemicals and Reagents
Acrylamide (A3553) was purchased from Sigma. Primary antibodies used for immunohistochemistry, goat polyclonal anti-8-hydroxydeoxyguanosine (8OHdG) antibody (Ab5830), and rabbit anti-CYP2E1 antibody (19937-1-AP), were purchased from Merck Millipore and Proteintech, respectively. Alexa Fluor 594 goat antirabbit IgG (A11012) was purchased from Life Technologies, and Alexa Fluor 594 donkey antigoat (A11058) was purchased from Invitrogen. Proteinase K (V3021) was purchased from Promega. Comet Assay LMAgarose (4250-050-02) was purchased from Trevigen. Agarose type VII low gelling temperature (A-4018) was purchased from Sigma. RQ1 RNase free DNase (M610A) was purchased from Promega. Dakin slides, fully frosted (G376), were purchased from ProSciTech. SYBR Green 1 nucleic acid gel stain (50513) was purchased from Lonza. TPA (P8139) and DMBA (D3254) were purchased from Sigma. Tris-glycine NG 4%-20% protein gels (NG11-420) were purchased from NuSep. Mini complete protease inhibitor cocktail tablets (11836153001) were purchased from Roche. Primary antibodies used for Western blot analysis, rabbit anti-CYP2E1 (orb39332) and rabbit anti-GAPDH (G9545), were purchased from Assay Matrix and Sigma, respectively. Goat horseradish peroxidase-conjugated antirabbit antibody (DC03L) was purchased from Merck Millipore. Amersham ECL Western blot analysis detection reagent (RPN2134) was purchased from VWR. Oligo (dT)15 primer, RNasin, dNTPs, M-MLV-Reverse Transcriptase, RQ1 DNase, GoTaq Flexi, MgCl 2 and GoTaq quantitative PCR master mix were obtained from Promega.
Animals
Experimental procedures involving animals were conducted in accordance with the policies set out by the Animal Care and Ethics Committee of the University of Newcastle (Ethics Number: A2012-222). Male Swiss CD-1 mice were 5-6 wk of age at the beginning of treatment with an average bodyweight of 34.7 g (SD ¼ 2.5), and were 31 wk old at completion of the study with an average bodyweight of 43.5 g (SD ¼ 3.0). Female Swiss CD-1 mice were 6-8 wk of age when first housed with males with an average bodyweight of 24.5 g (SD ¼ 1.5). All animals were housed under controlled temperature and humidity conditions, 16L:8D, with food and water provided ad libitum. Animals were acclimated for at least 1 wk prior to treatment.
Experimental Design
Six male mice were randomly assigned to two groups. Three mice were assigned to the control group and three were assigned to the acrylamidetreatment group. Acrylamide was administered via the drinking water. Acrylamide was diluted in Milli-Q water at a concentration of 1 lg/ml. This dose was chosen based on previous work that demonstrated an increase in DNA damage in the spermatocytes of male mice exposed to 1 lg/ml acrylamide for 6 mo [17] . Fresh acrylamide solutions were made on a weekly basis because acrylamide is stable in water for at least 1 wk [26] . Control mice were given Milli-Q drinking water. Treatment was ceased after 6 mo (24 wk) and each male mouse was given normal drinking water for 1 wk before being housed with two Swiss CD-1 female mice. After 1 wk being housed with the females, all male mice were euthanized. Testes were extracted and fixed in Bouin solution. Spermatozoa were extracted from the vas deferens into PBS by extracting the vas deferens and squeezing out the spermatozoa using forceps. Eleven litters were produced in total with only one female failing to become pregnant after being mated with an acrylamide-treated male. The number of pups per litter was counted, and all pups were weaned and sexed at 18-22 days, at which point, the males and females were housed separately.
Papilloma Induction
Upon weaning, all of the F1 mice (males and females) were then placed in a two-stage tumor-induction protocol originally established in 1994 by Yuspa [24] and still in use [25] . All mice in groups A, B, and C had an area shaved on their backs and were then treated topically in this area. Group A mice (positive control) were exposed to the tumor initiator DMBA (50 lg, one treatment) and group B received vehicle treatment (acetone). After 7 days, groups A and B mice were started on a once per week exposure to the tumor promoter TPA (10 lg/wk). Each dose was administered in 200 ll acetone. Group C mice received 200 ll vehicle on both occasions. The number of papillomas present was counted each week. We performed this trial on mice from each paternal exposure group (acrylamide or control) in order to link paternal exposure with predisposition to cancer. The experimental design of the two-stage tumorinduction protocol is outlined in Figure 2 .
A fourth group of F1 mice was also established upon weaning (group D). These mice were not administered acetone, TPA, DMBA, or any other treatment. They were housed in the same environment as the other F1 mice with weekly monitoring and no intervention. The F1 mice ranged from 24.6 wk old (172 days) to 27.1 wk old (190 days) when they were euthanized.
Alkaline Comet Assay
Spermatozoa were extracted from the vas deferens of mice immediately after euthanasia into PBS. DNA damage in isolated spermatozoa was performed as described by Katen et al. [27] . Spermatozoa were diluted 1 3 10 6 spermatozoa/ml in 25 mM Tris-HCl and 150 mM KCl, pH 7.5, supplemented with 0.25% Triton X-100, and 10 ll of the suspension was FIG. 2. Experimental design of study. Three male mice per group were treated with either 1 lg/ml acrylamide in their drinking water, or vehicle (Milli-Q water) control. These males were mated with unexposed females (2 per male), and the F1 progeny were split into four groups (A, B, C, and D). Groups A-C were included in the two-stage tumor-induction protocol. An area was shaved on the back of the mice where treatments were administered topically. Group A mice (positive control) were treated with the tumor initiator 7,12-dimethylbenz [a] anthracene (DMBA) (50 lg, one treatment), and group B received vehicle treatment (acetone). After 7 days, groups A and B mice were started on a once per week exposure to the tumor promoter 12-Otetradecanoylphorbol-13-acetate (TPA) (10 lg/wk). Group C mice received vehicle (acetone 200 ll) on both occasions. The number of papillomas present was counted each week. Mice in group D received no intervention and were monitored weekly.
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mixed with 70 ll of LMAgarose. Then 80 ll of the spermatozoa agarose suspension was spread onto fully frosted Dakin slides. These slides had previously been precoated with 70 ll of 1% low-gelling point agarose (A4018; Sigma) and allowed to dry. The spermatozoa and agarose mixture was then immediately covered with a coverslip and allowed to solidify at 48C for 1 h. Coverslips were then removed and slides were incubated in lysis solution 1 (0.8 M Tris-HCl, 0.8 M dithiothreitol, 1% SDS, pH 7.5), and then lysis solution 2 (0.4 M Tris-HCl, 50 mM ethylenediaminetetraacetic acid, 2 M NaCl, 0.4 M dithiothreitol, pH 7.5) for 30 min each at room temperature, and then washed in 0.445 M Tris-HCl, 0.445 M boric acid, 10 mM ethylenediaminetetraacetic acid for 10 min. The slides were then submerged in alkaline solution (0.03 M NaOH, 1 M NaCl) for 15 min at 48C and then electrophoresed at 1 V/cm in alkaline buffer (0.03 M NaOH) for 4 min. The slides were then washed in neutralization solution (0.4 M Tris-HCl, pH 7.5) for 5 min. Slides were stained with SYBR green, covered with a cover slip, and visualized under fluorescence on an Axio Imager A1 fluorescence microscope (Carl Zeiss MicroImaging Inc.). Images were taken using an Olympus DP70 microscope camera (Olympus America). The DNA integrity of 50 cells per slide was analyzed using Comet Assay IV software (Perceptive Instruments). The relative fluorescence intensity in the comet tail versus total intensity of the comet (tail DNA percent) was used as a measure of DNA damage. For F1 mice, all 46 samples could not be assessed in one run; the assay was therefore performed over five separate runs. Each run included four to six progeny of control and four to six progeny of acrylamide-treated biological replicates (10 samples per run). Fifty cells were analyzed per replicate and each value normalized to the average of the progeny of control values for that run. Therefore, the data is presented as percent increase compared to control (progeny of control-treated fathers) and is the mean of n ¼ 23 mice per group.
Immunohistochemistry
After extraction, mouse testes were fixed in Bouin solution, embedded in paraffin wax, and sectioned at 5 lm thickness. Sections were then deparaffinized and rehydrated before antigen retrieval was performed by incubation with trypsin working solution (0.05% trypsin and 0.1% CaCl 2 ) for 20 min at 378C. Sections were then blocked with 3% bovine serum albumin (BSA) in PBS with 0.05% Tween-20 (PBST) at room temperature for 1 h. Sections were then incubated with anti-CYP2E1 (1:500 with 1% BSA/PBST) or anti-8OHdG (1:100 with 1% BSA/PBST) overnight at 48C. Sections were washed and incubated with the appropriate fluorescent-conjugated secondary antibody (1:200 with 1% BSA/PBST) for 1 h at room temperature. Sections were counterstained with 0.5 lg/ml 6 0 -diamidino-2-phenylindole (DAPI) for 2 min. Slides were mounted in Mowiol 4-88 (475904; Calbiochem) prepared as follows: 2.4 g Mowiol to 6 g glycerol in 6 ml of water and 12 ml of 0.2 M phosphate buffer, pH 7.4, were heated to 508C for 30 min with constant mixing. The mixture was then cooled and added 0.1% n-propyl gallate (P3130; Sigma), then centrifuged at 5000 3 g for 15 min. Slides were then observed on an Axio Imager A1 fluorescence microscope. Images were taken using an Olympus DP70 microscope camera.
Fluorescence Quantification
ImageJ software was used to quantify the level of fluorescence for anti-CYP2E1 and anti-8OHdG used for immunohistochemical analyses as described previously [28] [29] [30] [31] [32] . For CYP2E1 expression, the spermatocytes in an individual tubule were circled and the corrected total cell fluorescence (CTCF) was calculated using the following formula: CTCF ¼ integrated density À (area of selected cells 3 mean fluorescence of background readings). This was performed for a total of 50 tubules per animal. The 8OHdG signal was assessed by circling the spermatocyte and spermatogonial population of cells for an individual tubule and determining the CTCF. This was repeated for the spermatid cells. A total of 25 tubules were assessed per animal.
Western Blot Analysis
Testis tissue was homogenized in SDS protein extraction buffer (0.3 M sucrose, 2% SDS, and 0.1875 M Tris in Milli-Q water with added protease inhibitor cocktail), boiled at 1008C for 5 min, and centrifuged for 10 min at 13 000 3 g. The protein lysate supernatant was collected and resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The membranes were blocked with 5% skim milk powder in 20 mM Tris and 150 mM NaCl with 0.5% Tween 20 (TBST) for 24 h at 48C, and then probed with anti-CYP2E1 (1:1000) or anti-GAPDH (1:5000) in 1% skim milk in TBST for 18 h at 48C or 1 h at room temperature, respectively. Membranes were washed in TBST (three times for 10 min), then probed with the goat horseradish peroxidase-conjugated antirabbit antibody (1:1000) for 1 h. Labeled proteins were then detected using Amersham ECL Western blot detection reagent. Densitometry was performed using ImageJ version 11. The mean of three technical replicates for each band was normalized to the mean of three technical replicates for the corresponding GAPDH band.
Quantitative PCR
RNA was extracted, DNase treated, and reverse transcription was performed as described in Nixon et al. [22] . Quantitative PCR was performed using the LightCycler 96 System (Roche Diagnostics) using 10 ll SYBR Green GoTaq Quantitative PCR master mix, 0.2 ll of 10 lM primers in a total reaction volume of 20 ll. The sequences of all primers used in this study are provided in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org). Reactions were performed on cDNA equivalent to 20 ng of total RNA and carried out for 45 amplification cycles. SYBR Green fluorescence was measured after the extension step at the end of each amplification cycle and quantified using LightCycler 96 System Software version 1.1. The normalized ratio for each sample was determined using the following formula: normalized ratio ¼
, where E T is the amplification efficiency of the target gene, E R is the amplification efficiency of the reference gene, Cq T is the quantification cycle of the target gene (Cyp2e1), Cq R is the quantification cycle of the reference gene (R 1 and R 2 were GusB and B2M, respectively), and cal is the run calibrator. Primer efficiencies and annealing temperatures were determined for each primer set using a standard curve. The normalized ratio was determined using two reference genes, Gusb and B2M. All data was then normalized to the control for that run.
Statistics
Statistical analyses were performed using JMP software version 11 (SAS Institute). Data was tested for normality using the Shapiro-Wilk test. When data was distributed in a Gaussian manner, as was found in Figures 1A, 3 , 9A, 9C, and 9D, a two-tailed t-test was performed. When data was not distributed in this manner, as was the case for Figures 1B, 4A, 4B , 5B, 6B, 7B, 8B, and 9B, the nonparametric Wilcoxon test was applied. P values , 0.05 were assigned *, P , 0.01 were assigned **, and P , 0.001 were assigned ***.
RESULTS
F0 Mouse Acrylamide Consumption
Treating male mice with a dose of 1 lg/ml acrylamide via drinking water for 6 mo had no overt negative health effects. Weekly monitoring of the weight of these mice revealed no differences throughout the duration of the study (Supplemental Fig. S1 ). Similarly, assessment of weekly water consumption and the calculated mean daily water consumption also remained the same throughout the observation period. These combined values (daily water consumption and bodyweight) were used to calculate the acrylamide dose (Supplemental Table S2 ), revealing that an average of 0.13 mg acrylamide/kg bw/day (SD ¼ 0.03) was consumed per mouse over the 24 wk of treatment. This value closely approximated the target of 0.15 mg acrylamide/kg bw/day, which was administered to mice for 6 mo by Nixon et al. [17] and found to elicit DNA damage in spermatocytes. Based on the formula recommended by the Food and Drug Administration for conversion of mouse NOAEL to HED [23] , we determined the HED for our study to be 10.5 lg/kg bw/day. This dose-translation formula is as follows: HED (mg/kg) ¼ animal dose (mg/kg) 3 animal K m / human K m , where K m factor ¼ weight (kg)/body surface area (m 2 ) and human weight and body surface area equal 60 kg and 1.6 m 2 , respectively (hence K m ¼ 37), and mouse weight and body surface area equal 0.02 kg and 0.007 m 2 , respectively (hence K m ¼ 3) [23, 33] . This acrylamide-treatment regime had KATEN ET AL. no detrimental effects on the male F0 mice, their overall fertility, or the growth of their progeny.
Chronic Acrylamide Treatment Has No Effect on Time to Fertilization and Litter Size of Male Mice
The reproductive NOAEL for acrylamide-induced reproductive toxicity is reported to be 5 mg/kg bw/day for reduced fertility and 2 mg/kg bw/day for premature embryonic death [16] . Because the dose selected for use in this study was much lower (0.13 mg/kg bw/day), it was not expected to overtly affect the fertility of the male mice. As seen in Supplemental Table S3 , there was no reduction in time to conception when treated males were mated with unexposed females, nor were there any changes in the size of the litters produced from these matings.
The gross bodyweight of the F1 mice were recorded on a weekly basis for 18 wk encompassing periods before and during the two-stage papilloma-induction treatment (Fig.  1A) . This failed to reveal any differences in offspring weight irrespective of whether the fathers had received acrylamidesupplemented or control drinking water. Similarly, there were also no differences in bodyweight observed among the F1 males at the completion of the study, nor was there any difference in testis to bodyweight ratio at this time point (Fig. 1B) . A) The alkaline comet assay was performed on spermatozoa of male mice after mating with unexposed females. A significant increase in DNA damage was observed with acrylamide treatment. B) The spermatozoa of the offspring of these mice were also assessed, and a significant increase in DNA damage was observed in mice whose fathers were exposed to acrylamide. The F1 results are shown as the combined mean value for n ¼ 23 mice per group after normalization to the respective controls of each assay run. FIG. 3 . Paternal acrylamide exposure did not lead to increased predisposition to skin cancer in the F1 generation. Mean number of papillomas in F1 mice in groups A, B, and C (experimental design outlined in Fig. 2 ) grouped based on paternal exposure to control or acrylamide. Mice in group A developed papillomas that increased in abundance from 7 wk of tumor promotion. Mice in groups B and C did not develop papillomas, regardless of the treatment of their F0 fathers. No significant difference was observed in group A based on the treatment of the F0 males; however, there was a trend for mice that were the progeny of acrylamide-treated males to have a higher number of papillomas than those whose fathers were controls. The number of papillomas for individual mice in group A after 15 wk of tumor promotion is represented in the table.
CHRONIC ACRYLAMIDE EXPOSURE AND THE MALE GERMLINE
FIG. 5. Chronic acrylamide exposure results in increased levels of 8OHdG adducts in the germ cells of male mice. Immunolocalization of 8OHdG was assessed in the testes of male mice exposed to acrylamide (A) by probing testis sections with anti-8OHdG and the appropriate secondary antibody (shown in red) and then counterstaining with DAPI (shown in blue), a nuclear marker. This was quantified by using ImageJ (B). The corrected total cell fluorescence (CTCF) was determined per tubule for spermatogonia (spg) and spermatocytes (spcytes) combined, as well as for spermatids by circling around the appropriate germ cell stages. This was performed for 25 tubules per animal. The CTCF values were normalized to the mean values for the
Chronic Paternal Acrylamide Exposure Does Not Lead to a Predisposition to Skin Cancer in the F1 Generation
The experimental design for the two-stage tumorinduction protocol is described in Figure 2 . Upon weaning, the male and female F1 mice commenced the two-stage skin papilloma-induction protocol. Mice which were born to acrylamide-or control-treated fathers were randomly allocated to four groups. Group A received DMBA once, followed by TPA once per week, group B received TPA, and group C received acetone topically once per week on a shaved area on their lower back. These mice were monitored for papilloma formation as shown in Figure 3 . The mice in group D were not administered any intervention.
After 7 wk of promotion with TPA, the mice in group A (DMBA) developed papillomas (Fig. 3) . The number of these papillomas increased steadily until the study was ceased after 15 wk of induction. Mice in group B, which were treated with TPA, regardless of their fathers' exposure to acrylamide, did not develop papillomas even after 15 wk of tumor promotion. There was also no background papilloma formation observed among the control mice in group C, which received only acetone treatment. Unexposed CD-1 mice do not ordinarily develop papillomas. Hence, acrylamide exposure in the male F0 mice did not result in an increase in papilloma formation in the F1 generation. However, it is interesting to note that the mice in group A (DMBA) whose fathers received acrylamide treatment had a trend for higher papilloma numbers compared to the mice whose fathers were sourced from the control group.
Chronic Acrylamide Treatment Leads to Sperm DNA Damage in Exposed Mice and Their Unexposed Offspring
Notwithstanding the lack of a fertility phenotype induced by chronic acrylamide exposure, we sought to determine whether this toxicant had any measurable impact on the integrity of the paternal genome within the germline. For this purpose, the spermatozoa of treated and control males were assessed using an alkaline comet assay, which is optimized for measurement of single-strand DNA breaks typical of those propagated by glycidamide adduction. As shown in Figure 4A , a significant 2.5-fold increase in the overall levels of DNA damage (tail DNA percent) were detected in the spermatozoa of mice treated with acrylamide for 6 mo. Importantly, the spermatozoa of F1 mice from acrylamide-treated sires also bore the hallmarks of elevated levels of DNA damage (Fig. 4B ) despite themselves having never been exposed to this insult.
Chronic Acrylamide Treatment Causes Increased Levels of Oxidative DNA Adducts in the Germ Cells of Male Mice and Their Offspring
In addition to its production of the metabolite glycidamide, the CYP2E1 enzyme also generates substantial quantities of reactive oxygen species (ROS) as a byproduct of the detoxification reactions it catalyzes. Thus, the presence, and relative levels, of oxidative DNA adducts were assessed in the testes of male mice treated with acrylamide. This analysis was performed using an immunofluorescence assay in which testes sections were probed with anti-8OHdG antibody prior to quantification of labeling intensity using ImageJ. Representative images of the 8OHdG expression levels detected in the testes of control-and acrylamide-treated mice are presented in Figure 5A and illustrate a clear elevation in the intensity of 8OHdG lesions recorded. Quantification of labeling intensity revealed a significant increase in oxidative adducts in the spermatogonia and spermatocytes as well as the spermatids of all acrylamide-treated mice (Fig. 5B) . A significant increase in positive 8OHdG labeling was also detected in all germ cell types of F1 male mice sired by acrylamide-exposed fathers, despite the fact they had not experienced any such intervention themselves (Fig. 6 ).
Chronic Acrylamide Treatment Causes Increased Expression of CYP2E1 in the Testes of Male Mice and in Their Offspring
Because CYP2E1 is the detoxifying enzyme exclusively responsible for metabolizing acrylamide into the more harmful product glycidamide, the relative expression of CYP2E1 was assessed in the testes of treated male mice and that of their control counterparts. As shown in Figures 7A and 8A, CYP2E1 predominantly localizes to populations of spermatocytes within the adult testis. Notably, 6 mo of acrylamide treatment resulted in a greater expression of CYP2E1 protein within these germ cells. Quantitative ImageJ assessment of immunofluorescent labeling intensity within these sections revealed that this striking change was indeed significant (P , 0.05, Fig. 7B ). Western blot analysis of CYP2E1 expression within whole testis was assessed (Fig. 9C ) and was quantified using ImageJ but no significant difference was found. However, there was a trend observed for higher CYP2E1 expression in the testes of acrylamidetreated mice. The more subtle change is expected to be a result of the need to assess whole testis protein levels because isolation of germ cell types was not possible. Quantitative PCR results of whole testis did not reveal any difference in Cyp2e1 gene expression within the testes of control and acrylamide-treated mice (Fig. 9A) . Hence, we were unable to determine whether the protein induction occurred as a result of increased gene expression without isolating specific germ cell types.
The significant upregulation of CYP2E1 expression in spermatocytes was recapitulated in the spermatocytes of F1 male mice whose fathers were exposed to acrylamide, despite the fact that they themselves had not been treated with this toxicant (Fig. 8, A and B) . This finding was further strengthened by the significant increase in CYP2E1 expression in whole testis quantified by Western blot analysis in Figure 9D . In this instance, with n ¼ 23 mice per group, a similar but not significant trend was observed for increased Cyp2e1 mRNA levels in the progeny of mice treated with acrylamide (Fig. 9B) , suggesting a link between 3 corresponding germ cell types for the controls. Biological replicates were n ¼ 3 as indicated. There was a significant increase in the expression of 8OHdG in the spermatogonia and spermatocyte stages as well as in spermatids of male mice directly exposed to acrylamide and in their offspring. All scale bars ¼ 100 lm.
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FIG. 6. The male progeny of acrylamide-treated mice had increased levels of 8OHdG adducts in all germ cell stages. A) Immunolocalization was performed as described in Figure 5 . B) The levels of 8OHdG were quantified using ImageJ as described in Figure 5 , and levels were higher in the spermatogonia/spermatocyte stages as well as spermatid stages of mice that were the progeny of acrylamide-treated males. Biological replicates were n ¼ 9 F1 mice per group. All scale bars ¼ 100 lm.
increased gene expression and protein expression in the F1 generation.
DISCUSSION
Acrylamide is neurotoxic to humans and is classified as a probable human carcinogen based on studies in mice and rats. Many studies have established the reproductive toxicity associated with acute acrylamide exposure in male mice, which results in reduced fertility and resultant dominant lethality of embryos [4, [8] [9] [10] 34] . Effects of subchronic acrylamide exposure have also been examined. Administration of acrylamide to male and female Fischer 344 rats for 10 wk at 5 mg/kg bw/day in both the F0 and F1 generations resulted in reduced embryo implantations, numbers of live births, and neonatal survival in the F1 rats [16] . The F2 animals suffered from a pronounced dominant lethality phenotype [16] . Similarly, elevated doses of 6.7 mg/kg bw/ day acrylamide administered to male and female CD-1 mice for a period of 27 wk resulted in reduced litter sizes [35] .
These studies do not capture the effects of acrylamide exposure that reflect the nature of human exposure to this toxicant. Humans are typically exposed to acrylamide in a chronic manner via their diet [12, 36] , which results in a lifetime of exposure at an estimated dose of 1-4 lg/kg bw/ day [13] . Chronic exposure to toxicants can result in accumulated effects such that cellular defense mechanisms are gradually eroded and DNA damage can accumulate in vulnerable cells such as the germline [37] . Damage to the germline has consequences for future generations. In seeking to provide new insight into such responses, the current multigenerational study employed a unique experimental design study modeled on both the length and route of acrylamide administration that was considered most relevant to human exposure. Major points of differentiation from previous studies include restriction of treatment to male mice within the F0 generation only, use of a chronic exposure length, and adoption of a dose that falls much lower than previously assessed in studies proceeding beyond the F0 generation. This dose approaches the current human dietary intake estimates and has previously been demonstrated to elicit DNA damage in germ cells equivalent to the levels of damage observed with 9 or 12 mo of acrylamide exposure at the human consumption estimate equivalent dose (0.0015 mg/kg bw/day) [17] .
Building on the previous work by Nixon et al. [17] , we have now demonstrated that chronic acrylamide treatment resulted in DNA damage in the spermatozoa. It is hypothesized that this DNA damage occurred during spermatogenesis, with acrylamide being converted to glycidamide via CYP2E1 in the spermatocytes. Because repair mechanisms are less active in postmeiotic germ cells [38] [39] [40] [41] [42] , this damage persisted in the resultant spermatozoa. Homologous DNA repair is no longer active in postmeiotic germ cells. Round spermatids are still capable of nonhomologous DNA end joining, and elongating spermatids and spermatozoa are unable to repair DNA damage such as single-strand breaks [42, 43] . The adducts caused the DNA strands to break, forming single-strand breaks, which were detected in the spermatozoa by the alkaline comet assay. As further evidence for the role of CYP2E1 in this damage, treatment with resveratrol, an inhibitor of CYP2E1, has been demonstrated to ameliorate chronic acrylamide-induced DNA damage in spermatozoa [27] .
The DNA damage that accompanied chronic acrylamide exposure in the current study was found to have no effect on fertility, with sperm count, motility, and morphology all being normal. From these data, we infer that the spermatozoa of treated males retained their capacity for fertilization. Similarly, the DNA damage carried by these spermatozoa must have remained below the threshold necessary for induction of an overt dominant lethality phenotype in the resultant embryos. While extensive sperm DNA damage can result in reduced fertility, spontaneous abortion, and impaired or abnormal fetal development, as is the case with acute acrylamide exposure, more subtle effects have been demonstrated to occur in offspring conceived of spermatozoa with compromised DNA integrity as a result of either chemical or radiation exposure [44] . Spermatozoa carrying substantial levels of DNA damage have been demonstrated to retain their capacity for fertilization [45] . Because we failed to record any reduction in pup numbers per litter, it was considered unlikely that the level of DNA damage present in the spermatozoa from our treated F0 males resulted in embryo losses. Furthermore, the resultant offspring demonstrated normal growth trajectory and development.
The frequency of germline mutations in the F1 mice whose fathers were treated with acrylamide was not sufficient to elicit papillomas when the tumor promoter TPA was dermally administered for 15 wk. We propose that chronic acrylamide exposure induced epigenetic alterations in the paternal epigenome, which were inherited in the offspring and may be contributing to the apparent increase in skin papilloma formation in group A. This finding warrants further investigation in future studies and led us to investigate other indications of damage to the male germline in the F1 mice and hence to investigate the DNA damage in their spermatozoa.
Our intergenerational analysis of papilloma induction raises the possibility that the DNA damage borne by the paternal genome was capable of being recognized and resolved by efficient repair pathways present in the oocyte, and thus failed to persist into the F1 generation. In this context, it is well established that the female gamete is endowed with a number of DNA repair enzymes required for nucleotide excision repair, single-strand break and double-strand break repair, and base excision repair, which become active following fertilization [46] . Thus DNA mutational loads as high as 30% are still deemed compatible with fertilization [47] . Alternatively, it is possible that such lesions may have been misrepaired or escaped repair but remained latent within the germline of the F1 mice. Our germline analysis supports the latter conclusion. Indeed, we demonstrated that the male F1 mice also had increased levels of DNA damage in their spermatozoa. While the extent of DNA damage was below that recorded in the F0 fathers, it was nonetheless significantly elevated beyond that of progeny conceived from untreated control males. These findings constitute the first evidence that chronic acrylamide exposure in male mice results in DNA damage in the germline of untreated sons.
In terms of the mechanisms of action through which such DNA damage is propagated, our data supports previous evidence from acute studies that this involves bioconversion of acrylamide into its highly reactive metabolite glycidamide [10, 19, 20] . In cells, this conversion is exclusively catalyzed via the activity of CYP2E1, a member of the cytochrome P450 oxidase system that act as terminal oxidases for metabolizing a number of xenobiotics [48] . CYP2E1 is most highly expressed in the liver, with lower levels expressed in extrahepatic tissues such as the brain, CHRONIC ACRYLAMIDE EXPOSURE AND THE MALE GERMLINE FIG. 7 . Chronic acrylamide exposure results in increased levels of CYP2E1 protein in the spermatocytes of male mice. A) Immunolocalization of CYP2E1 was assessed in the testes of male mice exposed to acrylamide by probing testis sections with anti-CYP2E1 and the appropriate secondary antibody (shown in red) and then counterstaining with DAPI (shown in blue), a nuclear marker. CYP2E1 was localized primarily to the spermatocytes. B) CYP2E1 expression was quantified using ImageJ. A total of 50 individual tubules were assessed per animal. The corrected total cell fluorescence (CTCF) for a circled area containing only the spermatocytes was calculated. All values were normalized to the CTCF for control animals. All scale bars ¼ 200 lm.
kidneys, and testes [49] . CYP2E1 has a large number of substrates, some of which, including acetone, ethanol, and toluene, result in induction of the enzyme [50] [51] [52] [53] . Our previous studies demonstrated a significant upregulation of Cyp2e1 mRNA expression in spermatocytes following an in vitro acrylamide challenge, suggesting that transcriptional induction may be the principle mechanism by which acrylamide stimulates increased CYP2E1 protein expression within the testis [22] . Here we have extended these findings by demonstrating that whole animal exposure to acrylamide can also potently induce CYP2E1 expression in spermatocytes in vivo. Consistent with our previous work, the elevated levels of CYP2E1 protein were predominantly localized within the spermatocyte population of testicular germ cells. The increased CYP2E1 protein levels were also demonstrated in the progeny of acrylamide-treated mice, despite these mice having no direct exposure to acrylamide. These findings were reinforced by the induction of CYP2E1 detected by Western blot analysis in whole testes. In addition, a trend was noted for increased Cyp2e1 mRNA levels in the progeny of acrylamide-treated mice. This did not reach significance, however; an explanation for this is that mRNA levels were measured for the whole testis because isolated germ cells were not able to be assessed. Hence, the effect was diluted by the inclusion of all testis cell types, including germ cells and somatic cells, rather than assessing individual germ cell populations. Indeed, Nixon et al. [22] demonstrated that Cyp2e1 gene expression occurs predominantly in spermatogonia whereas protein expression is found in spermatocytes.
As mentioned, the predominant pathway for removal of acrylamide from cells is via conversion to glycidamide in a detoxification process catalyzed by CYP2E1 [54, 55] . In phase I metabolism, acrylamide is oxidized to glycidamide. During phase II, glycidamide and any remaining acrylamide are conjugated with glutathione via the glutathione-Stransferase enzyme. These conjugates are then metabolized to mercapturic acids and removed via phase III excretion in the urine. The downside to this process is that bioactivation occurs in phase I because glycidamide is more toxic than its parent compound. Glycidamide is thus capable of forming strong covalent adducts with guanine and adenine nucleotides within the DNA backbone before conjugation and excretion can occur. Acrylamide, on the other hand, can only form adducts with proteins [54, 56] . While it is not surprising that chronic assault by acrylamide results in an upregulation of the CYP2E1 protein in the spermatocytes, this is ultimately detrimental because it promotes enhanced rates of conversion to glycidamide. It is therefore highly concerning that increased CYP2E1 expression is an inheritable characteristic of the F1 generation, which themselves have never been directly exposed to acrylamide. If this mechanism were to be propagated over many generations, then each generation would potentially be more vulnerable to acrylamide-induced damage than the last. Such a scenario is particularly alarming in humans because we are routinely exposed to acrylamide throughout our lifetime.
An explanation for these findings is that chronic acrylamide exposure induced epigenetic modifications, which was inherited by the offspring. A number of studies have investigated the role of epigenetic regulation in the expression of CYP2E1. Indeed, microRNAs have been proposed to play a role in regulating the gene expression of drug metabolizing and xenobiotic metabolizing enzymes such as cytochrome P450s, contributing to their toxicity [57, 58] . Human CYP1B1 and CYP3A4 have been demonstrated to be regulated posttranscriptionally by miR-27b [59, 60] and CYP2E1 by miR-378 [61] . CYP2E1 expression is also known to be regulated by DNA methylation, which was first described in humans during early development. Hypermethylation of important sequences from the Cyp2e1 gene present in fetal liver have been found to be associated with null expression, and demethylation of this region was found to cause a gradual increase in expression in later development [62] . A study by Jiménez-Garza et al. [63] has determined that smokers have a higher level of methylation of the CYP2E1 promoter than nonsmokers. They also detected a negative correlation between CYP2E1 promoter methylations and levels of chronic toluene exposure. Toluene is a known inducer of CYP2E1 [53] . While it is unclear which epigenetic mechanism may be playing a role in the upregulation of CYP2E1 in the current study, there is certainly potential for this to be a contributing factor.
In addition to the prevalence of DNA damage presumably elicited by glycidamide, we also noted significantly increased levels of oxidative DNA adducts (8OHdG) in the germ cells of both F0 acrylamide-treated mice and their offspring. As demonstrated, the oxidative damage was predominantly found in cells expressing CYP2E1 and are therefore considered most likely to have arisen as a byproduct of the ROS generated by the enzyme during its oxidative detoxification of acrylamide [64] . Consistent with this notion, it is well established that overexpression or induction of CYP2E1 activity leads to the generation of higher levels of ROS even in the absence of any substrate for the enzyme [65] . In fact, the level of superoxide and H 2 O 2 produced by microsomes from CYP2E1-expressing cells was found to be equivalent in both the presence and absence of substrate and ligands of the CYP2E1 enzyme [66] . Taken together, these findings emphasize the potential detrimental impact for the F1 mice to have inherited an increased basal level of CYP2E1 production within their testes. At present, it remains to be determined whether these oxidative adducts could have worked synergistically with glycidamide to produce the single-strand breaks detected in the spermatozoa of the F0 mice.
In conclusion, this study was undertaken to test the hypothesis that chronic acrylamide treatment of male mice would result in damage to the germline and negatively impact the health of the subsequent generation. Commensurate with this hypothesis, we recorded elevated levels of DNA damage, encompassing both oxidative adducts in the germ cells and single-strand breaks, in the spermatozoa of treated males. Moreover, we demonstrated that DNA damage is also present in the spermatozoa of F1 mice, which were not directly exposed to acrylamide. The key mechanism responsible for eliciting such damage appeared to rest with an impressive upregulation of the CYP2E1 detoxification enzyme within the spermatocyte population and its subsequent generation of glycidamide and/or ROS. Importantly, this increased CYP2E1 expression was also detected in the F1 generation, potentially pointing to occurrence of epigenetic alterations. The novel discovery of this priming effect, whereby the increased expression levels of CYP2E1 and increased levels of DNA damage within the germline can be elevated over multiple generations, is of real concern as it raises the prospect of incremental amplification of this response should subsequent generations encounter acrylamide challenge themselves.
CHRONIC ACRYLAMIDE EXPOSURE AND THE MALE GERMLINE FIG. 8 . The progeny of acrylamide-treated mice had increased levels of CYP2E1 protein expression in the spermatocytes. A) Immunolocalization of CYP2E1 was performed as described in Figure 7 . B) ImageJ quantification was performed as described in Figure 7 for n ¼ 9 mice per treatment. All scale bars ¼ 200 lm.
Nevertheless, over the time course and dosing regimen adopted for our study, chronic acrylamide administration did not elicit adverse reproductive outcomes or impact on the health of the subsequent generation.
